# Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

> **NCT03554291** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 80 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Right Heart Failure

## Interventions

- **DRUG:** Famotidine 20 MG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03554291
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2023-07-11
- **Final completion:** 2023-07-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03554291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03554291, "Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03554291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*